ADOCIA

innovative medicine
for everyone, everywhere

PRESS RELEASE

# Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog

## Adocia and Lilly Terminate Collaboration

**Lyon, France, July 29, 2013 -** Adocia (NYSE Euronext Paris: FR0011184241 - ADOC), a biotechnology company specializing in the development of 'best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone® technology for the formulation of fast acting insulin analog formulated with the BioChaperone® technology. Consequently, the two companies have terminated the collaboration.

"*We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone® technology*" said Gérard Soula, President and CEO.

"*Our plan is to test a BioChaperone® insulin analog formulation on type I diabetic patients. For this, we intend to conduct, before year end in Germany, a clinical trial on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet®, our formulation of human insulin*" said Olivier Soula, Deputy General Manager and Director R&D.

The company has a strong financial position enabling the development of this priority project at its own expense.

### Next scheduled events

**September 5, 2013:** Publication of mid-year financial statements as of June 30, 2013.
**September 6, 2013:** Presentation meeting to investors (SFAF).

## About Adocia :

***"Innovative medicine for everyone, everywhere"***

Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.

Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing).

Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.

Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.

***To be a global leader for the formulation of therapeutic proteins***

Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.

Adocia's therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.

Adocia is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index.

For more information: www.adocia.com


**Contact**

Gérard Soula - contactinvestisseurs@adocia.com
Chairman and CEO of Adocia
Tél. : +33 4 72 610 610

**Press Relations**
**Andrew Lloyd & Associates**
Juliette dos Santos - juliette@ala.com
Tél. : +33 1 56 54 07 00

**Financial communication & Investor Relations**
**NewCap**
Pierre Laurent - plaurent@newcap.fr
Tél. : +33 1 44 71 94 94